Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Top navigation

  • News
    • Company Statements
    • Media Contact
    • Email Alerts
  • Investors
    • Events & Presentations
    • Financials
    • Stock Information
    • Governance
    • Resources
  • Responsibility
    • Compliance & Transparency
  • Contact Us
    • Our Locations
    • Medical Information
  • Country List
SEARCH
Home

Main navigation

  • Our Company
    • Commitment & Responsibility
  • What We Do
    • Global Portfolio
    • Hematology/Oncology
    • Dermatology
    • Our Medicines
    • Partnerships
  • Culture & Careers
  • HCP Resources
  1. Home
  2. What We Do
  3. Our Medicines
  • SEARCH
  • Our Company
    • Commitment & Responsibility
  • What We Do
    • Global Portfolio
    • Hematology/Oncology
    • Dermatology
    • Our Medicines
    • Partnerships
  • Culture & Careers
  • HCP Resources
  • News
    • Company Statements
    • Media Contact
    • Email Alerts
  • Investors
    • Events & Presentations
    • Financials
    • Stock Information
    • Governance
    • Resources
  • Responsibility
    • Compliance & Transparency
  • Contact Us
    • Our Locations
    • Medical Information
  • United States

Incyte International Locations

NORTH AMERICA—HEADQUARTERS

DENMARK

ITALY

SPAIN

UNITED KINGDOM

EUROPE—HEADQUARTERS

FINLAND

JAPAN

SWEDEN

AUSTRIA

FRANCE

THE NETHERLANDS

SWITZERLAND

CANADA

GERMANY

NORWAY

PORTUGAL

Close

Interior of a lab
Interior of a lab
Interior of a lab

Our Medicines

  • Hematology/Oncology Therapies

Iclusig® (ponatinib)

Learn More >

Minjuvi® (tafasitamab)

Learn More >

Pemazyre® (pemigatinib)

Learn More >

  • Dermatology Therapies

Opzelura® (ruxolitinib) 

Learn More >

Our Global Portfolio

HCP Resources
Footer Logo

May 2024 DE/CCA/NP/24/0004 © 2012-2024 Incyte.

  • Facebook Icon
  • LinkedIn Icon
  • Twitter Icon
  • Youtube Icon
  • Impressum
  • Legal Notice
  • Privacy Policy
  • Cookie Policy
  • Suppliers
  • Site Map